GC said that the Ministry of Food and Drug Safety has approved using Peramiflu, an intravenous influenza treatment, to treat infants aged six months to two years.

The approval came as BioCryst, the raw material manufacturer for Peramiflu, proved its safety and efficacy to the U.S. Food and Drug Administration and received approval for age-extended use.

“The approval marks the first time that a local injection-type flu treatment received approval for the age group,” the company said. “The approval of Peramiflu is also significant as it provides a new treatment option for patients at a young age who have difficulty taking oral treatments."

Peramiflu, launched in 2010, is an antiviral drug that treats influenza A and B virus infections. Unlike oral medications that require 10 doses for five days, the product treats the flu with just one injection.